AgroAmerica Supports Higher Education to Help Reduce Migration in Latin America
24.3.2021 14:00:00 EET | Business Wire | Press release
The Agribusiness food company, AgroAmerica, is sponsoring the 100K Innovation Fund grant competition for higher education projects aimed at universities in The United States, Central America and the Dominican Republic.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210324005218/en/
The 100,000 Strong in the Americas Innovation Fund Grant Competition for higher education, promoted by the Bureau of Western Hemisphere Affairs of the U.S. Department of State and supported by AgroAmerica, the U.S. Embassy in Guatemala, and the NGO Partners of the Americas, aims to impulse education initiatives through innovative models of academic training and student exchange programs between the United States and Central America & Dominican Republic, beginning in January 2022. Institutions of higher education in the United States and Guatemala, El Salvador, Honduras, Costa Rica, Panama, Belize, Nicaragua, and the Dominican Republic are invited to submit their 100K grant proposals to Partners of the Americas at 100kstrongamericas.org/grants before August 2, 2021. (Photo: Business Wire)
The 100K Innovation Fund New Grant Competition is sponsored by the Bureau of Western Hemisphere Affairs of the U.S. Department of State and supported by AgroAmerica, the U.S. Embassy in Guatemala and the NGO Partners of the Americas. The 100K Fund will be awarded in 12 grants of $25,000 this year to support new higher education projects.
AgroAmerica is the second multinational company in Guatemala to join this public-private initiative. The company's CEO, Fernando Bolaños Valle, said that "it is with great enthusiasm that AgroAmerica joins the State Department as a strategic partner in this regional initiative, in an organic way, because of our shared values; building, through educational programs, a more prosperous future full of hope for our countries… we are convinced that the future of our continent depends on strategic investments like these, which will multiply prosperity for the United States, Guatemala and the region."
Javier Aguirre, corporate director of AgroAmerica, explained that the company donated funds to strengthen local capacities in the areas of climate change, human rights, natural resource management, sustainable agriculture, conservation and reforestation, environmental protection and sustainable businesses.
"The new 100K Strong Americas Innovation Fund partnerships, supported by AgroAmerica and the Department of State, will grow the number of students in the United States, Central America and the Dominican Republic, so working together, they will acquire valuable new skills and knowledge and grow our economies," said Julie Chung, acting assistant secretary of the Bureau of Western Hemisphere Affairs at the U.S. Department of State.
About the 100K Innovation Fund
The 100,000 Strong in the Americas Innovation Fund is the public-private sector collaboration between the Department of State, U.S. embassies and Partners of the Americas to promote a positive agenda for the region by harnessing the power of education.
About AgroAmerica
AgroAmerica is an agribusiness company dedicated to the production and commercialization of food products, through the use of sustainable and responsible cultivation methods. It operates in Europe, the United States, Mexico, Guatemala, Ecuador, Peru, and Panama. The Company's Corporate Sustainability Strategy aims to generate value and balance between economic growth, natural resource conservation, and the wellbeing of customers, employees, and stakeholders.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210324005218/en/
Contact information
Javier Aguirre
Corporate Director
comunicacion@agroamerica.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom